HomeBUSINESS
BUSINESS

Mogamulizumab Bags US Approval for Mycosis Fungoides, Sézary Syndrome: Kyowa Kirin
(Aug.10.2018)

Kyowa Hakko Kirin said on August 9 that the US FDA has approved its anti-CCR4 monoclonal antibody mogamulizumab, known as Poteligeo, for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome who have had at least one prior systemic therapy ...
(LOG IN FOR FULL STORY)